MAR 29, 2018 1:30 PM PDT

Cannabidiol Treatment of Epilepsy and Autism Through Restoration of GABAergic Signaling

Speaker

Abstract

Cannabidiol (CBD) has emerged as a promising anti-epileptic drug in otherwise treatment-resistant genetic epileptic disorders. However, the clinical trials have been limited by their use of CBD only as an add-on therapy, their lack of assessment of CBD on comorbid phenotypes, and their lack of insight into CBD’s therapeutic mechanism. To address these limitations, we tested CBD’s effects on behavior and physiology in our genetic mouse model of Dravet Syndrome (DS). DS is a severe childhood epileptic disorder characterized by treatment resistant epilepsy, as well as cognitive and social deficits consistent with autism. Our DS mice recapitulate these core behavioral phenotypes and are thus a powerful precision medicine tool to test the efficacy of CBD as a monotherapy in DS. We find that acute CBD administration reduced the thermally-induced seizures that model febrile seizures in the early stage of DS. Twice-daily CBD administration also reduced the frequency of spontaneous seizures that characterize the later stages of DS.

These anti-epileptic effects were associated with an enhancement in GABAergic signaling in the dentate gyrus of the hippocampus, which is mediated by CBD antagonism of GPR55 signaling. Furthermore, we find that CBD rescued social interaction deficits and abnormal social responses in our DS mice. Together, our data suggest that CBD is an effective monotherapy against epileptic seizures and autism in DS. Our results also reveal that GPR55 signaling is an important target for CBD’s therapeutic benefits.

Learning Objectives:

  •  Be able to describe cannabidiol's benefits as a monotherapy in treating epilepsy and autism
  •  Understand the cellular mechanism by which cannabidiol rescues brain function that's disrupted   by genetic mutations
     

Show Resources
You May Also Like
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
MAR 16, 2022 8:00 AM PDT
C.E. CREDITS
MAR 16, 2022 8:00 AM PDT
Date: March 16, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CET) Handling of potent and/or hazardous substances is commonplace in sev.....
NOV 30, 2021 10:00 AM PST
C.E. CREDITS
NOV 30, 2021 10:00 AM PST
Date: November 30, 2021 Time: 10:00am (PDT), 1:00pm (EDT) The prevalence of thyroid disease worldwide has served as a catalyst for healthcare providers to study various tools and methods to...
APR 26, 2022 7:00 AM PDT
C.E. CREDITS
APR 26, 2022 7:00 AM PDT
Date: April 19, 2022 Time: 7:00am (PDT), 10:00am (EDT), 4:00pm (CEST) High-content (HC) phenotypic profiling approaches are a powerful tool to study the effect of biological, genetic, and ch...
MAR 30, 2022 6:00 AM PDT
MAR 30, 2022 6:00 AM PDT
Targeted NGS has been instrumental in helping the healthcare community deliver on the promise of precision medicine. The Ion Torrent Genexus Integrated Sequencer has enabled targeted genomic...
MAR 16, 2022 9:00 AM PDT
C.E. CREDITS
MAR 16, 2022 9:00 AM PDT
Date: March 16, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 6:00pm (CEDT) With a renewed and growing interest in therapeutic oligonucleotides (oligos) across the pharmaceutical industry, the req...
MAR 29, 2018 1:30 PM PDT

Cannabidiol Treatment of Epilepsy and Autism Through Restoration of GABAergic Signaling



Show Resources
Loading Comments...
Show Resources